Profile cover photo
Profile photo
Vishal Manchanda
3 followers
3 followers
About
Posts

Post has attachment

Post has attachment
Novartis - Glivec Generics Impact: Consensus Estimates Are Way Too Pessimistic
Consensus is significantly overestimating potential adverse impact on Novartis earning post entry of Glivec generics. Consensus fails to appreciate the details with regard to competitive dynamics. Novartis 2016 earnings are highly sensitive to performance o...
Add a comment...

Post has attachment
GSK's first biological Asthma treatment a potential megablockbuster?
Nucala was recently approved by the USFDA and EMA for the treatment of patients with severe Asthma of eosinophilic phenotype. In the base case, Nucala should reach peak sales of $2b. If Nucala is approved in other indications (COPD, HES) too, it can garner ...
Add a comment...

Post has attachment
Analyzing potential generic competition for Advair
Advair is  GSK 's largest selling drug. It sells around $4.6b annually worldwide. The drug is currently facing generic competition in Europe, however the impact not been very painful until now as 1) Copy-cat versions launched by generic companies are not su...
Add a comment...

Post has attachment
Add a comment...

Post has attachment
Wait while more posts are being loaded